Your browser doesn't support javascript.
loading
Remission of organ failure in patients with predicted severe acute pancreatitis treated by somatostation, octreotide and cyclooxygenase-2 inhibitors.
Huang, Zhi-Yin; Gong, Hui; Tang, Cheng-Wei; Wang, Mo-Jin; Wang, Rui.
Afiliación
  • Huang ZY; Departments of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
  • Gong H; Departments of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
  • Tang CW; Departments of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China.
  • Wang MJ; Gastric Cancer Center, West China Hospital, Sichuan University, Chengdu, China.
  • Wang R; Departments of Gastroenterology, West China Hospital, Sichuan University, Chengdu, China. Electronic address: wangruifisher@163.com.
Pancreatology ; 24(1): 24-31, 2024 Feb.
Article en En | MEDLINE | ID: mdl-38155082
ABSTRACT

BACKGROUND:

/

Objectives:

Persistent organ failure (OF) in severe acute pancreatitis (SAP) is caused by activation of cytokine cascades, resulting in inflammatory injury. Anti-inflammation may be helpful in OF remission in early SAP. To assess the efficacy of anti-inflammatory regimens for OF prevention and remission in patients with predicted SAP and display clinical doctors' acceptance of these strategies, we conducted this retrospective study in the real world.

METHODS:

Clinical data of patients with predicted SAP from 2010 to 2017 were retrospectively reviewed. Cases were divided into conventional support (C), C+ somatostatin/octreotide (C + S/O), and C + S/O + Cyclooxygenase-2-inhibitors (C + S/O + COX-2-I). The occurrence of SAP, OF, changes of proportion for three strategies, length of hospital stay, meperidine injection, and cytokine levels were compared. The constituent ratios of the three schemes over eight years were evaluated.

RESULTS:

A total of 580 cases (C = 124, C + S/O = 290, C + S/O + COX-2-I = 166) were included. The occurrences of SAP in the C + S/O (28.3 %) and C + S/O + COX-2-I (18.1 %) groups were significantly lower than that in C group (60.5 %, P < 0.001), mainly by reducing persistent respiratory failure (P < 0.001) and renal failure (P = 0.002). C + S/O and C + S/O + COX-2-I regimens significantly decreased new onset OF and enhanced OF amelioration within 48 h when compared with C treatment (P < 0.001) in patients with OF score <2 and ≥ 2 on admission, respectively. C + S/O and C + S/O + COX-2-I as compared with C group significantly decrease OF occurrences in a multivariate logistic regression analysis (P < 0.05).

CONCLUSIONS:

Somatostatin or its analogs and cyclooxygenase-2 inhibitors are promising for OF prevention and remission in patients with predicted SAP. The acceptance of combined strategies in the real world has increased, and the occurrence of SAP has decreased annually.
Asunto(s)
Palabras clave

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Pancreatitis Límite: Humans Idioma: En Revista: Pancreatology Asunto de la revista: ENDOCRINOLOGIA / GASTROENTEROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: China

Texto completo: 1 Bases de datos: MEDLINE Asunto principal: Pancreatitis Límite: Humans Idioma: En Revista: Pancreatology Asunto de la revista: ENDOCRINOLOGIA / GASTROENTEROLOGIA Año: 2024 Tipo del documento: Article País de afiliación: China